TL
Therapeutic Areas
Coherus BioSciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| UDENYCA® (pegfilgrastim-cbqv) | Neutropenia in patients receiving myelosuppressive chemotherapy | Approved |
| YUSIMRY™ (adalimumab-aqvh) | Rheumatoid Arthritis, Psoriasis, Crohn's Disease, and other inflammatory conditions | Approved |
| Toripalimab | 1L recurrent or metastatic nasopharyngeal carcinoma (NPC) | BLA Submitted |
| CHS-006 | Advanced solid tumors | Phase 1 |
| CHS-1000 | Advanced solid tumors | Preclinical |
| CHS-1020 | Advanced solid tumors | Preclinical |
Leadership Team at Coherus BioSciences
DM
Dennis M. Lanfear
President, Chief Executive Officer, and Chairman of the Board
BM
Bryan McMichael
Chief Financial Officer
PR
Paul Reider
Chief Commercial Officer
MS
McDavid Stilwell
Chief Corporate Affairs & Communications Officer
PK
Paul Kang
General Counsel
BK
Barbara K. Finck
Chief Medical Officer
VL
Vicki L. Sato
Board Member
BD
Barbara D. Duncan
Board Member
JO
James O. Armitage
Board Member
JG
John G. Gargiulo
Board Member